Project detail

Novel Liposome-Based Platform for CRISPR/Cas9 Delivery

Duration: 01.03.2022 — 28.02.2023

Funding resources

Brno University of Technology - Vnitřní projekty VUT

- whole funder (2022-01-01 - 2023-12-31)

On the project

Gene therapy using CRISPR/Cas9 is not accessible and equitable. That is due to complicated and costly ex vivo therapeutical process caused by the lack of versatile delivery platform able to be used systemically in vivo. In this project I will develop liposome-based delivery platform consisting of several types of lipids and pH sensitive structure enabling controlled release of CRISPR/Cas9 into cytoplasm. This liposome will be tested for gene knock-out. The proposed platform can be easily functionalized for cell-specific delivery or theranostics

Mark

CEITEC VUT-J-22-8056

Default language

Czech

People responsible

Heger Zbyněk, doc. - fellow researcher
Ressnerová Alžběta, M.Sc., MSc - principal person responsible

Units

Central European Institute of Technology BUT
- beneficiary (2022-01-01 - 2022-12-31)
Smart Nanodevices
- internal (2022-01-01 - 2022-12-31)

Responsibility: Ressnerová Alžběta, M.Sc., MSc